Key result
Natriuretic peptides serve as reliable diagnostic tools and strong prognostic indicators for patients with congestive heart failure, with potential future roles in early detection and treatment guidance.
Natriuretic peptides serve as reliable diagnostic and prognostic markers for patients presenting with acute dyspnea and congestive heart failure.
Answers are grounded in this paper and cite their sources.
Supports diagnostic use in acute dyspnea; leaves open prospective validation for treatment guidance.
Congestive heart failure (CHF) is a progressive disease whose outcome largely depends on early, accurate and prompt diagnosis, accompanied by evidence-based treatment. The explosion of uptake of natriuretic peptides (NPs) in clinical practice belies an understanding of how peptides are used. The signal for NP release is the same signal that causes symptoms of CHF, such as increased wall stress. Thus, NPs can reliably add to the information a physician brings to the table as they attempt to diagnose the acutely dyspneic patient with CHF. Additionally, NPs have strong prognostic utility in the emergency room and the hospital. Monitoring of NPs during treatment for acute CHF may help manage the patient. In the future, it is possible that NPs will play a more prominent role in early detection of left ventricular dysfunction as well as guiding chronic CHF treatment.
No takes yet. Share an insight, caveat, or question.
Isakson et al. (2006) conducted a review in Congestive heart failure (CHF). Natriuretic peptides (NPs) was evaluated. Natriuretic peptides serve as reliable diagnostic tools and strong prognostic indicators for patients with congestive heart failure, with potential future roles in early detection and treatment guidance.
Synapse has enriched 10 related papers. Consider them for comparative context: